Aromatase inhibitors as adjuvant therapies in patients with breast cancer
- 1 September 2003
- journal article
- review article
- Published by Elsevier in The Journal of Steroid Biochemistry and Molecular Biology
- Vol. 86 (3-5) , 309-311
- https://doi.org/10.1016/s0960-0760(03)00372-8
Abstract
No abstract availableKeywords
This publication has 12 references indexed in Scilit:
- Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trialThe Lancet, 2002
- Estrogen-receptor-directed neoadjuvant therapy for breast cancer: Results of a randomised trial using formestane and methotrexate, mitozantrone and mitomycin C (MMM) chemotherapyAnnals of Oncology, 2001
- Tamoxifen for early breast cancer: an overview of the randomised trialsThe Lancet, 1998
- Ovarian ablation in early breast cancer: overview of the randomised trialsThe Lancet, 1996
- Assessment of the effect of pretreatment with neoadjuvant therapy on primary breast cancerBritish Journal of Cancer, 1996
- Adjuvant aminoglutethimide for postmenopausal patients with primary breast cancer: analysis at 8 years.Journal of Clinical Oncology, 1992
- 4-HYDROXYANDROSTENEDIONE IN TREATMENT OF POSTMENOPAUSAL PATIENTS WITH ADVANCED BREAST CANCERThe Lancet, 1984
- LOW-DOSE AMINOGLUTETHIMIDE IN TREATMENT OF ADVANCED BREAST CANCERThe Lancet, 1984
- Inactivation of aromatase in vitro by 4-hydroxy-4-androstene-3,17-dione and 4-acetoxy-4-androstene-3,17-dione and sustained effects in vivoSteroids, 1981
- Aminoglutethimide Inhibits Extraglandular Estrogen Production in Postmenopausal Women with Breast Carcinoma*Journal of Clinical Endocrinology & Metabolism, 1978